{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:35:49Z","timestamp":1792442149876,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study was designed to evaluate the efficiency and tolerability of empagliflozin (EMPA) as monotherapy or add-on to existing therapy in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Randomized controlled trials (RCTs) comparing efficacy and safety of EMPA vs placebo or EMPA plus other antidiabetes drugs vs placebo plus other oral antidiabetes drugs (OADs) in T2DM were recruited from electronic database Pubmed, Web of Knowledge, and Cochrane Central Register of Controlled Trials (CENTRAL), supplemented by a hand search of the reference lists of selected articles. Main effect sizes were change from baseline on glycemia control, body weight, blood pressure, and complications (i.e., incidence of urinary and genital tract infections, and morbidity of hypoglycemia and hyperglycemia). Random-effects model was used to account for clinical or methodologic heterogeneity across studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifteen RCTs with a total number of 7891 individuals (5374 in EMPA group and 2517 in control group) were suitable for this meta-analysis. The results demonstrated that significant improvements in glycemia control, body weight, and blood pressure were associated with EMPA application (i.e., monotherapy and add-on therapy) in patient with T2DM when compared with placebo. Meanwhile, EMPA 10 and 20\u200amg improved glycemia, body weight, and blood pressure control for patients with T2DM. There was no significant difference in incidence of hypoglycemia and urinary tract infections across EMPA and placebo group. Significant reduced risk of hyperglycemia was revealed in EMPA group vs placebo (risk ratio: 0.34, 95%confidence interval: 0.23\u20130.49, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001), except in patients on background insulin therapy. However, increased risk of genital infection was noted across EMPA vs placebo (risk ratio: 2.59, 95% confidence interval: 1.80\u20133.71, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Our evidence supports the application of EMPA in treatment of patients with T2DM who are obesity or at risk of weight gain.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000012843","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T04:23:25Z","timestamp":1540441405000},"page":"e12843","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of empagliflozin for type 2 diabetes mellitus"],"prefix":"10.1097","volume":"97","author":[{"given":"Yun-Jing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Liang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Feng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zibo Central Hospital, Zibo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yankuang Group General Hospital, Zoucheng"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Zibo Central Hospital, Zibo, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2337\/dc14-2365","article-title":"Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes","volume":"38","author":"Lewin","year":"2015","journal-title":"Diabetes Care"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.12469","article-title":"Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial","volume":"17","author":"Ross","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial","volume":"40","author":"Softeland","year":"2017","journal-title":"Diabetes Care"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/00325481.2017.1259544","article-title":"Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"129","author":"Devi","year":"2017","journal-title":"Postgrad Med"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00228-016-2010-8","article-title":"Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis","volume":"72","author":"Zhong","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.clinthera.2016.03.031","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Kohler","year":"2016","journal-title":"Clin Ther"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/dom.12081","article-title":"A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes","volume":"15","author":"Ferrannini","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R14-20230914","first-page":"154","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume":"35","year":"2014","journal-title":"Online Kensaku"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12325-014-0126-8","article-title":"Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial","volume":"31","author":"Kadowaki","year":"2014","journal-title":"Adv Ther"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diabetes Care"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo","year":"2015","journal-title":"Diabetes Care"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Fischereder","year":"2016","journal-title":"N Engl J Med"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1517\/14656566.2015.1009445","article-title":"Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus","volume":"16","author":"Lewin","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.diabres.2015.05.044","article-title":"Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes","volume":"110","author":"Haering","year":"2015","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201810260-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:39:32Z","timestamp":1694716772000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201810260-00019"}},"subtitle":["Meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":30,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000012843","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}